Mastercard Incorporated (NYSE:MA ) Barclays 15th Annual Emerging Payments and FinTech Forum May 19, 2025 9:10 AM ET Company Participants Raj Seshadri - Chief Commercial Payments Officer Conference Call Participants Peter Ramsey - Barclays Investment Bank Peter Ramsey We are honored to have Raj Seshadri, Chief Commercial Payments Officer of Mastercard here with us. Raj, thank you so much for joining us.

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI ) Q1 2025 Earnings Conference Call May 19, 2025 8:30 AM ET Company Participants Joyce Lonergan - Investor Relations, LifeSci Advisors Chaim Lebovits - President & Chief Executive Officer Haro Hartounian - Executive Vice President & Chief Operating Officer Bob Dagher - Executive Vice President & Chief Medical Officer Netta Blondheim-Shraga - Senior Vice President, Research & Development Conference Call Participants Jason McCarthy - Maxim Group David Bautz - Zacks Small-Cap Operator Greetings, and welcome to the Brainstorm Cell Therapeutics First Quarter 2025 Conference Call. At this time, all participants are in a listen-only mode.

Tesla's (NASDAQ: TSLA) stock may be headed for rougher valuation terrain before it climbs higher, according to Morgan Stanley analyst Adam Jonas.

AEVA inked a major deal with a Fortune 500 tech firm, set to invest $50 million, $32.5 million in equity and $17.5 million in product development and scaling production.

Canal 13 leverages QMCO's Myriad and ActiveScale to unify storage, boost efficiency and protect content against disruptions.

Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.

Declining commodity price realizations have hurt YPF's Q1 earnings.

Stantec (STN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Roblox (RBLX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Intercorp Financial Services (IFS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Examine Steris' (STE) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

Examine GoPro's (GPRO) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

Explore Exelixis' (EXEL) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Review Cisco's (CSCO) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Explore how Applied Materials' (AMAT) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Explore how Brink's' (BCO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

NEW YORK, NY / ACCESS Newswire / May 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cable One, Inc. ("Cable One, Inc.") (NYSE:CABO) concerning possible violations of federal securities laws. On May 2, 2025, Cable One missed earnings expectations by nearly $8 and suspended its dividend.

NEW YORK, NY / ACCESS Newswire / May 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cleveland-Cliffs Inc. ("Cleveland-Cliffs Inc.") (NYSE:CLF) concerning possible violations of federal securities laws. Cleveland-Cliffs issued a press release on May 7, 2025, reporting its financial results for the first quarter of 2025.

NEW YORK, NY / ACCESS Newswire / May 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.

Last week's economic data presented a mixed bag, arriving against a backdrop of an S&P 500 that trended upwards for the entire week, buoyed by positive developments in trade talks.